Latest filing published 03 Mar 2026 for Intellia Therapeutics, Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of David Lebwohl in Intellia Therapeutics, Inc., where the filings describe the role as senior executive. We count 36 filings; the first trade dates from 9 August 2021 and the latest from 1 March 2026.
Every open-market trade on record is a sale: 21 sales worth €2.1M. Other entries cover 5 share grants and 10 option exercises. In 2026 alone, the filings show no purchases and 1 sale.
Most recently, on 3 March 2026, the filings show a share grant in Intellia Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
18 of 18 declarations